Cargando…
Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare...
Autores principales: | Hayek, Samah, Ben-shlomo, Yatir, Dagan, Noa, Reis, Ben Y., Barda, Noam, Kepten, Eldad, Roitman, Alina, Shapira, Shachar, Yaron, Shlomit, Balicer, Ran D., Netzer, Doron, Peretz, Alon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344792/ https://www.ncbi.nlm.nih.gov/pubmed/35918340 http://dx.doi.org/10.1038/s41467-022-32253-9 |
Ejemplares similares
-
Indirect protection of children from SARS-CoV-2 infection through parental vaccination
por: Hayek, Samah, et al.
Publicado: (2022) -
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021) -
Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021) -
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022) -
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
por: Arbel, Ronen, et al.
Publicado: (2022)